UPF
11.5.2021 07:02:09 CEST | Business Wire | Press release
World leaders and experts joined more than a million global participants for the launch of “Think Tank 2022” on May 9 KST during the virtual 6th Rally of Hope for the peaceful reunification of the Korean Peninsula.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510006060/en/
The rally, sponsored by the Universal Peace Federation (UPF), was streamed live from South Korea to 194 nations and translated into 14 languages. Think Tank 2022 is a global multi-sector network of more than 2,000 experts from a wide range of fields—government, business, academia, faith, media, arts and culture—dedicated to the collaborative search for solutions to the world’s most critical challenges.
World-class leaders including the rally’s 12 keynote speakers affirmed and enhanced the concept of Think Tank 2022. “This network will make a difference for peace on the Korean Peninsula through international unity,” said Ban Ki-Moon , former United Nations Secretary-General and chairman of the new initiative. “I applaud Dr. Hak Ja Han Moon, UPF, and the leaders of Think Tank 2022.”
Former European Commission President José Manuel Barroso reminded the audience, that “peace also includes goodwill, trust and justice. The foundation of peace is each human being. The coronavirus taught us the lesson that we have to act and cooperate on a global scale.” “As leaders from around the world who cherish the values of faith, family, democracy and justice under law,” said former U.S. Vice President Mike Pence . “I commend you for coming together at this event to continue to sow the seeds of peace, believing that in time we will reap a harvest of peace that will benefit the people of Korea, the United States and all mankind.”
Born in present-day North Korea, UPF co-founders Dr. Hak Ja Han Moon and her late husband, Rev. Dr. Sun Myung Moon, fled to the south during the Korean War and have devoted their lives to advancing a more peaceful world and reuniting Korea. Think Tank 2022, will spearhead peacebuilding initiatives such as a UN Peace Park on the DMZ; building a Korea-Japan undersea tunnel; boosting Geumgang Mountain tourism development; and helping separated Korean families find their relatives.
“A reunified, denuclearized Korean Peninsula will bring massive peace and prosperity to the peninsula and to the region,” said Mike Pompeo , former U.S. Secretary of State and CIA Director. “Religious freedom is indeed the foundation of all freedoms...with prayer, faith, and commitment to the Lord, peace will follow.”
Many speakers, including former Republic of Korea Prime Minister Chung Sye-Kyun and Cambodian Prime Minister Hun Sen , praised the timeliness of Think Tank 2022 where “international cooperation and solidarity is needed now more than ever,” said Chung.
From Africa, Zanzibar President Dr. Hussein Ali Mwinyi recalled that Africans took part in the Korean War and long for peace and democracy in that region. The peaceful reunification of Korea will lead to “explosive growth,” said renowned American businessman and investor Mr. Jim Rogers . “If trains run through the DMZ and cars run on highways, there will be endless economic development opportunities...benefiting not only the two Koreas, but also China, Russia, Japan and Asia and the whole world.”
Mr. David Beasely , executive director of the United Nations World Food Programme, the world’s largest humanitarian organization and 2020 recipient of the Nobel Peace Prize, said, “This rally is reaching across continents, uniting people all over the world in a spirit of peace, mutual prosperity and public service.”
Governments have failed because they couldn’t go beyond “their bureaucracies, their biases, and their fears,” said Newt Gingrich , former U.S. Speaker of the House of Representatives. Think Tank 2022 offers a new way for people from multiple nations to work together “outside the traditional, formal structures” he said.
“Times of crisis often tend to be the moments of greatest opportunity,” said Mark Esper , former U.S. Secretary of Defense.
"Prof. Sarah Gilbert , co-developer of the Oxford/Astra-Zeneca vaccine said that great advances would result from the challenge of the pandemic, including much speedier development of vaccines to cope with new and mutant viruses. Much greater cooperation between nations was needed to ensure the effective roll-out of the currently available vaccines to nations afflicted by the pandemic as well as greater generosity on the part of richer nations to poorer ones".
The 6th Rally of Hope, part of a digital series started by Dr. Moon in August 2020, has brought together tens of millions of people worldwide who embrace freedom, peace, and unity based on the shared ideals of interdependence, mutual prosperity, and universal values. The Washington Times article on the rally is available here .
Rally of Hope Website (video with highlights of the event): https://www.rallyofhope.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510006060/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
